Newest BioTech

Newest Biotech is a clinical-stage biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing its proprietary iNeo platform, the company integrates artificial intelligence and high-throughput sequencing to identify and design patient-specific neoantigens. Their pipeline includes personalized neoantigen peptide vaccines, mRNA vaccines, and neoantigen-reactive T cell therapies (iNeo-T) targeting various solid tumors. Headquartered in Suzhou, China, Newest Biotech aims to advance precision oncology by tailoring treatments to the unique genetic profile of each patient's tumor. The company has established collaborations with several clinical institutions to validate its neoantigen prediction algorithms and therapeutic efficacy.